

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版
Akamatsu S, Hayes CN, Tsuge M, <u>Miki D</u> , Akiyama R, Ochi H, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K.	Differences in serum microRNA profiles in hepatitis B and C virus infection.	J Infect	70(3)	273-87	2015
Honda Y, Takahashi S, Zhang Y, Ono A, Murakami E, Shi N, Kawaoka T, <u>Miki D</u> , Tsuge M, Hiraga N, Abe H, Ochi H, Imamura M, Aikata H, Chayama K.	The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.	J Gastroenterol Hepatol	30(3)	619-27	2015
Akamatsu S, Hayes CN, Tsuge M, Murakami E, Hiraga N, Abe H, <u>Miki D</u> , Imamura M, Ochi H, Chayama K; Hiroshima Liver Study Group.	Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism.	J Viral Hepat	22(2)	166-74	2015
Kosaka K, Imamura M, Hayes CN, Abe H, Hiraga N, Yoshimi S, Murakami E, Kawaoka T, Tsuge M, Aikata H, <u>Miki D</u> , Ochi H, Matsui H, Kanai A, Inaba T, Chayama K.	Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.	J Viral Hepat	22(2)	158-65	2015

Tanimine N, Tanaka Y, Kobayashi T, Tashiro H, <u>Miki D</u> , Imamura M, Aikata H, Tanaka J, Chayama K, Ohdan H.	Quantitative Effect of Natural Killer-Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy.	Cancer Immunol Res	2(12)	1142-7	2014
Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, Kan H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Honda Y, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hyogo H, Aikata H, Takahashi S, <u>Miki D</u> , Ochi H, Ohishi W, Chayama K; Hiroshima Liver Study Group.	Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.	J Gastroenterol	49(12)	1548-56	2014
Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, <u>Miki D</u> , Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K.	Two patients treated with pegylated interferon/ribavirin /telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.	Hepatol Res	44(12)	1259-64	2014

Kohno T, Tsuge M, Murakami E, Hiraga N, Abe H, <u>Miki D</u> , Imamura M, Ochi H, Hayes CN, Chayama K.	Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA.	J Viral Hepat	21(9)	e89-97	2014
Ochi H, <u>Miki D</u> , Hayes CN, Abe H, Hayashida Y, Kubo M, Chayama K.	IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population.	J Gen Virol	95(Pt 6)	1297-306	2014
Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, <u>Miki D</u> , Ochi H, Matsui H, Kanai A, Inaba T, McPhee F, Chayama K.	Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.	Antimicrob Agents Chemother	58(4)	2105-12	2014